Tyrosine kinase inhibitors (TKI) have completely changed the prognosis of patients with Ph+ chronic myeloid leukemia (CML). The occurrence of a second malignancy (SM) in CML patients successfully treated with TKI may significantly affect their prognosis. In a retrospective study of 1,038 patients with CML treated at 10 centers in the Czech Republic and Slovakia between 2000 and 2009, SM was detected in 35 (3.37%) patients after TKI therapy was initiated. The median intervals from the diagnosis of CML and from the start of TKI therapy to the diagnosis of SM were 58 months (range 2 - 214) and 32 months (range 1 - 102), respectively. The observed age-standardized incidence of SM after the start of TKI therapy was 8.95 / 1,000 person-years. Comparison of the incidence of SM in CML patients with population data was performed only for patients from the Czech Republic. The age-standardized incidence rate of all malignant tumors except non-melanoma skin cancers was 6.76 (95% CI: 6.74; 6.78) / 1,000 person-years in 2000 - 2007 while the incidence rate of SM in 708 CML patients from the Czech Republic treated with TKI was 9.84 (95% CI: 6.20; 13.48) / 1,000 person-years, i.e. 1.5-fold higher, although the difference was statistically insignificant. The distribution of SM types in CML patients treated with TKI was similar to that in the age-standardized general Czech population. The median overall survival (OS) of patients treated with TKI who also developed SM (57 months) was shorter than the OS of patients treated with TKI but not suffering from SM (median OS not reached, log rank test p < 0.001. Prospective long-term population-based studies in CML patients treated with TKI as first-line therapy are needed to determine the relationship of SM to KTI therapy.

2nd Department of Internal Medicine Division of Hematolgy University Hospital Hradec Králové Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc12027736

003      

CZ-PrNML

005      

20170615131635.0

007      

ta

008      

120817s2011 xo f 000 0#eng||

009      

AR

024    7_

$a 10.4149/neo_2011_03_256 $2 doi

035    __

$a (PubMed)21395367

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xo

100    1_

$a Voglová, Jaroslava $7 xx0084091 $u 2nd Department of Internal Medicine, Division of Hematolgy, University Hospital Hradec Králové, Czech Republic. voglava@fnhk.cz

245    10

$a Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia / $c J. Voglova, J. Muzik, E. Faber, D. Zackova, H. Klamova, K. Steinerova, Z. Michalovicova, L. Demitrovicova, E. Cmunt, L. Novakova, E. Tothova, P. Belohlavkova, J. Mayer, K. Indrak,

520    9_

$a Tyrosine kinase inhibitors (TKI) have completely changed the prognosis of patients with Ph+ chronic myeloid leukemia (CML). The occurrence of a second malignancy (SM) in CML patients successfully treated with TKI may significantly affect their prognosis. In a retrospective study of 1,038 patients with CML treated at 10 centers in the Czech Republic and Slovakia between 2000 and 2009, SM was detected in 35 (3.37%) patients after TKI therapy was initiated. The median intervals from the diagnosis of CML and from the start of TKI therapy to the diagnosis of SM were 58 months (range 2 - 214) and 32 months (range 1 - 102), respectively. The observed age-standardized incidence of SM after the start of TKI therapy was 8.95 / 1,000 person-years. Comparison of the incidence of SM in CML patients with population data was performed only for patients from the Czech Republic. The age-standardized incidence rate of all malignant tumors except non-melanoma skin cancers was 6.76 (95% CI: 6.74; 6.78) / 1,000 person-years in 2000 - 2007 while the incidence rate of SM in 708 CML patients from the Czech Republic treated with TKI was 9.84 (95% CI: 6.20; 13.48) / 1,000 person-years, i.e. 1.5-fold higher, although the difference was statistically insignificant. The distribution of SM types in CML patients treated with TKI was similar to that in the age-standardized general Czech population. The median overall survival (OS) of patients treated with TKI who also developed SM (57 months) was shorter than the OS of patients treated with TKI but not suffering from SM (median OS not reached, log rank test p < 0.001. Prospective long-term population-based studies in CML patients treated with TKI as first-line therapy are needed to determine the relationship of SM to KTI therapy.

650    _2

$a mladiství $7 D000293

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a senioři nad 80 let $7 D000369

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    _2

$a incidence $7 D015994

650    _2

$a chronická myeloidní leukemie $x farmakoterapie $7 D015464

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a sekundární malignity $x epidemiologie $7 D016609

650    _2

$a inhibitory proteinkinas $x terapeutické užití $7 D047428

650    _2

$a tyrosinkinasy $x antagonisté a inhibitory $7 D011505

650    _2

$a retrospektivní studie $7 D012189

651    _2

$a Česká republika $x epidemiologie $7 D018153

651    _2

$a Slovenská republika $x epidemiologie $7 D018154

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Muzik, J

700    1_

$a Faber, Edgar, $d 1956- $7 xx0062699

700    1_

$a Zackova, D

700    1_

$a Klamova, H

700    1_

$a Steinerova, K

700    1_

$a Michalovicova, Z

700    1_

$a Demitrovicova, L

700    1_

$a Cmunt, E

700    1_

$a Novakova, L

700    1_

$a Tothova, E

700    1_

$a Belohlavkova, P

700    1_

$a Mayer, J

700    1_

$a Indrák, Karel, $d 1947- $7 jn20000401162

773    0_

$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 58, č. 3 (2011), s. 256-62

856    41

$u https://pubmed.ncbi.nlm.nih.gov/21395367 $y Pubmed

910    __

$a ABA008 $b A 1194 $c 659 $y m $z 0

990    __

$a 20120817 $b ABA008

991    __

$a 20170615132049 $b ABA008

999    __

$a ok $b bmc $g 949778 $s 785082

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2011 $b 58 $c 3 $d 256-62 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470

LZP    __

$a Pubmed-20120817/11/03